J&J handling of Propulsid examined

An investigative report published in this morning's New York Times looks at how Johnson & Johnson handled safety problems with the heartburn drug Propulsid after the company learned of evidence suggesting possible risks with the drug. According to the paper, the drug giant continued to market the drug even as evidence mounted that the medicine posed serious health dangers, particularly for children. The report also notes that the FDA knew of evidence that the drug was less effective than advertised, but did not make it public. This suggests that J&J has changed since its swift reaction to the Tylenol crisis some two decades ago.

- see this story from The New York Times